Download PDF
CC BY 4.0 · Brazilian Journal of Oncology 2022; 18: e-20220300
DOI: 10.5935/2526-8732.20220300
Review Article
Clinical Oncology

Safe prescription of systemic antineoplastic treatment in oncology: integrative literature review

Prescrição segura do tratamento antineoplásico sistêmico em oncologia: revisão integrativa da literatura
Fabiola Vasconcelos Alves 
1   University of Brasilia, Faculty of Health Sciences - Brasilia - Federal District - Brazil
,
Renata Cristina de Campos Pereira Silveira
2   University of São Paulo, Department of General and Specialized Nursing - Ribeirão Preto - São Paulo - Brazil
,
Flavia Oliveira de Almeida Marques da Cruz
3   University of Federal District, University Center of Federal District - Brasilia - Federal District - Brazil
,
Elaine Barros Ferreira
1   University of Brasilia, Faculty of Health Sciences - Brasilia - Federal District - Brazil
,
Paula Elaine Diniz dos Reis
1   University of Brasilia, Faculty of Health Sciences - Brasilia - Federal District - Brazil
› Author Affiliations Financial support: None to declare.
› Further Information
   Permissions and Reprints All articles of this category

ABSTRACT

The objective of this study was to identify the available evidence on the parameters that should be considered to improve the quality and safety of the prescription of systemic antineoplastic treatment. This is an integrative review carried out in the EMBASE, LILACS, and PubMed databases, from 2015 to 2019. The methodological quality of the included studies was assessed by the tools of the Joanna Briggs Institute. Eight studies were included, of which 5 addressed adverse events related to systemic antineoplastic treatment, including 4,970 patients treated with immunotherapy, target therapy, and chemotherapy. One study assessed the safety of prescribing antineoplastic agents and 2 studies addressed pharmacovigilance and risk management by assessing treatment- related adverse effects. Chemotherapy, target therapy, and immunotherapy have different toxicity profiles. The evidence suggests that assessment of treatment toxicity as well as risk management should be considered to improve the quality and safety of prescribing systemic antineoplastic treatment.

RESUMO

O objetivo deste estudo foi identificar as evidências disponíveis sobre os parâmetros que devem ser considerados para melhorar a qualidade e a segurança da prescrição do tratamento antineoplásico sistêmico. Trata-se de uma revisão integrativa realizada nas bases de dados EMBASE, LILACS e PubMed, no período de 2015 a 2019. A qualidade metodológica dos estudos incluídos foi avaliada pelas ferramentas do Instituto Joanna Briggs. Oito estudos foram incluídos, dos quais 5 abordaram eventos adversos relacionados ao tratamento antineoplásico sistêmico, incluindo 4.970 pacientes tratados com imunoterapia, terapia alvo e quimioterapia. Um estudo avaliou a segurança da prescrição de agentes antineoplásicos e 2 estudos abordaram a farmacovigilância e o gerenciamento de risco avaliando os efeitos adversos relacionados ao tratamento. Quimioterapia, terapia-alvo e imunoterapia têm perfis de toxicidade diferentes. As evidências sugerem que a avaliação da toxicidade do tratamento, bem como o gerenciamento de risco, devem ser considerados para melhorar a qualidade e a segurança da prescrição do tratamento antineoplásico sistêmico.

Keywords:

Antineoplastic agents - Immunotherapy - Drug-related side effects and adverse reactions - Patient safety

Descritores:

Agentes antineoplásicos - Imunoterapia - Efeitos colaterais e reações adversas relacionados a medicamentos - Segurança do paciente


Publication History

Received: 02 September 2021

Accepted: 05 November 2021

Article published online:
22 February 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

Bibliographical Record
Fabiola Vasconcelos Alves, Renata Cristina de Campos Pereira Silveira, Flavia Oliveira de Almeida Marques da Cruz, Elaine Barros Ferreira, Paula Elaine Diniz dos Reis. Safe prescription of systemic antineoplastic treatment in oncology: integrative literature review. Brazilian Journal of Oncology 2022; 18: e-20220300.
DOI: 10.5935/2526-8732.20220300
 

  • REFERENCES

  • 1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; May; 71 (03) 209-249
    Search in Google Scholar
  • 2 Ministry of Health (BR), National Cancer Institute José Alencar Gomes da Silva (INCA). Estimate 2020: cancer incidence in Brazil. Cancer statistics [Internet]. Rio de Janeiro: Ministry of Health/INCA; 2020. ;[access in 2020 Dec 28]. Available from: https://www.inca.gov.br/numeros-de-cancer
    Search in Google Scholar
  • 3 Scullin P, Devlin O, Forde C. Improving the safety of chemotherapy prescribing in oncology through the introduction of an assessment proforma. BMJ Qual Improv Rep 2017; Mar; 6 (01) u216501.w7906
    Search in Google Scholar
  • 4 Patel H, Gurumurthy P. Improving medication safety in onc ology care: impact of clinical pharmacy interventions on optimizing patient safety. Int J Clin Pharm 2019; Aug; 41 (04) 981-992
    Search in Google Scholar
  • 5 Brahmer JR, Lacchetti C, Schneider BJ, Gardner JM. Management of immune- related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; Jun; 36 (17) 1714-1768
    Search in Google Scholar
  • 6 Otero MJ, Vera R, González-Pérez C, Ayala de la Peña F, Peñuelas A, Quer N. Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients. Farm Hosp 2018; Nov; 42 (06) 261-268
    Search in Google Scholar
  • 7 Galvão TF, Pereira MG. Revisões sistemáticas da literatura: passos para sua elaboração. Epidemiol Serv Saúde 2014; Mar; 23 (01) 183-184
    Search in Google Scholar
  • 8 Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ 2009; 339: b2700
    Search in Google Scholar
  • 9 Joanna Briggs Institute (JBI). Manual for evidence synthesis [Internet]. Adelaide: JBI;; 2020. ;[access in ANO Mês dia]. Available from: https://jbi-global-wiki.refined.site/space/MANUAL
    Search in Google Scholar
  • 10 Joanna Briggs Institute (JBI). Checklist for systemic reviews and research syntheses [Internet]. Adelaide: JBI; 2020. ;[access in 2020 Aug 7]. Available from: https://joannabriggs.org/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Systematic_Reviews2017_0.pdf
    Search in Google Scholar
  • 11 Aguiar JP, Borges FC, Murteira R, Ramos C, Gouveia E, Passos J. et al. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma. Int J Clin Pharm 2018; Jun; 40: 852-861 https://doi.org/10.1007/s11096-018-0665-1
    Search in Google Scholar
  • 12 Canale ML, Camerini A, Huqi A, Lilli A, Bisceglia I, Parrini I. et al. Cardiovascular risk factors and timing of anthracyclines and trastuzumab cardiac toxicity. Anticancer Res 2019; 5745: 5741-5745
    Search in Google Scholar
  • 13 Desjardin M, Bonhomme B, Le Bail B, Evrard S, Brouste V, Desolneux G. et al. Hepatotoxicities induced by neoadjuvant chemotherapy in colorectal cancer liver metastases: distinguishing the true from the false. Clin Med Insights Oncol 2019; Jan; 13: 1-10
    Search in Google Scholar
  • 14 Dranitsaris G, Mazzarello S, Smith S, Vandermeer L, Bouganim N, Clemons M. Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. Support Care Cancer 2015; Apr; 24 (04) 1563-1569
    Search in Google Scholar
  • 15 Tervonen HE, Chen TYT, Lin E, Boyle FM, Moylan EJ, Della-Fiorentina SA. et al. Risk of emergency hospitalisation and survival outcomes following adjuvant chemotherapy for early breast cancer in New South Wales, Australia. Eur J Cancer Care (Engl) 2019; Sep; 28 (05) e13125
    Search in Google Scholar
  • 16 Ali AK, Watson DE. Pharmacovigilance assessment of immune-mediated reactions reported for checkpoint inhibitor cancer immunotherapies. Pharmacotherapy 2017; Nov; 37 (11) 1383-1390
    Search in Google Scholar
  • 17 Belachew SA, Erku DA, Mekuria AB, Gebresillassie Melaku B. Pattern of chemotherapy-related adverse effects among adult cancer patients treated at Gondar University Referral Hospital, Ethiopia: a cross-sectional study. Drug Healthc Patient Saf 2016; Dec; 8: 83-90
    Search in Google Scholar
  • 18 Man J, Ritchie G, Links M, Lord S, Lee CK. Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: a meta-analysis. Asia-Pac J Clin Oncol 2018; Jun; 14 (03) 141-152
    Search in Google Scholar
  • 19 National Chemotherapy Advisory Group (NCAG), Department of Health. Chemotherapy services in England: ensuring quality and safety [Internet]. London: NCAG; 2009. ;[access in ANO Mês dia]. Available from: https://www.theacp.org.uk/news/22-aug-2009-ncag-report-published
    Search in Google Scholar
  • 20 Clinical Oncological Society of Australia (COSA). Guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy [Internet]. Sydney: COSA;; 2017. ;[access in ANO Mês dia]. Available from: https://www.cosa.org.au/media/1093/cosa_guidelines_safeprescribingchemo2008.pdf
    Search in Google Scholar
  • 21 Society for Immunotherapy of Cancer (SITC). SITC cancer immunotherapy guidelines [Internet]. Milwaukee: SITC; 2021. ;[access in ANO Mês dia]. Available from: https://www.sitcancer.org/research/cancer-immunotherapy-guidelines
    Search in Google Scholar
  • 22 General Medical Council (GMC). GMC updates: good practice in prescribing and managing medicines and devices [Internet]. London: GMC;; 2021. ;[access in ANO Mês dia]. Available from: https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/good-practice-in-prescribing-and-managing-medicines-and-devices-updated
    Search in Google Scholar
  • 23 Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS. et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol 2018; Aug; 36 (22) 2326-2347
    Search in Google Scholar
  • 24 National Confidential Enquiry into Patient Outcome and Death (NCEPOD). For better, for worse? A review of the care of patients who died within 30 days of receiving systemic anti-cancer therapy [Internet]. London: NCEPOD; 2008. ;[access in ANO Mês dia]. Available from: https://www.ncepod.org.uk/2008sact.html
    Search in Google Scholar
  • 25 Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM. et al. American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 2012; May; 30 (14) 1715-1724
    Search in Google Scholar
  • 26 Eastern Cooperative Oncology Group (ECOG). ECOG performance status scale [Internet]. Philadelphia: ECOG; 2021. ;[access in 2020 Aug 7]. Available from: https://ecog-acrin.org/resources/ecog-performance-status
    Search in Google Scholar
  • 27 National Institutes of Health (NIH), National Cancer Institute (NCI). U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0 [Internet]. Bethesda: NIH/NCI; 2017. ;[access in 2020 Aug 7]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
    Search in Google Scholar
  • 28 Puzanov I, Diab A, Abdallah K, Bringham CO, Brogdon C, Dadu R. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; Nov; 5 (98) 95
    Search in Google Scholar